The Complainant is one of the biggest global pharmaceutical and healthcare groups. It provides solutions to address the evolving needs of patients worldwide by developing and delivering innovative medical treatments and drugs. The Complainant, with headquarter in Switzerland, created in 1996 through a merger of two other companies Ciba-Geigy and Sandoz, is the holding company of the Novartis Group. The Complainant’s products are manufactured and sold in many countries worldwide, including in the United States of America, a country where it has an active presence through its subsidiaries and associated companies.<\/p>\n
The Complainant is the owner of the registered well-known trademark NOVARTIS in numerous jurisdictions all over the world. The vast majority of these trademark registrations predate the registration of the disputed domain name <novartis.cfd>.<\/p>\n
Previous UDRP panels have stated that the NOVARTIS trademark is well-known (see Novartis AG v. Amartya Sinha, Global Webs Link, Novartis RO, WIPO Case No. D2020-3203).<\/p>\n
The Complainant owns numerous domain names composed of its trademark NOVARTIS alone, including <novartis.com> (registered in 1996), <novartis.us> (registered in 2002) or in combination with other terms, such as <novartispharma.com> (registered in 1999). The Complainant uses these domain names to resolve to its official websites through which it informs Internet users and potential consumers about its NOVARTIS mark and its related products and services. The Complainant also enjoys a strong presence online via its official social media platforms.<\/p>\n
The disputed domain name <novartis.cfd> (hereinafter “disputed domain name”) was registered on September 2, 2022 and resolves to a PPC page.<\/p>\n
According to the Registrar verification, the Respondent is frank disk. The Respondent’s provided address as being at Maryville, United States.<\/p>", "other_legal_proceedings": "
The Panel is not aware of any other legal proceedings which are pending or decided and which relate to the disputed domain name.<\/p>", "no_response_filed": "
COMPLAINANT:<\/p>\n
The Complainant contends that the disputed domain name is confusingly similar to Its NOVARTIS well-known and distinctive trademark. The Complainant owns NOVARTIS trademarks registered in numerous jurisdictions, which were registered many years before the registration of the disputed domain name on September 2, 2022, such as but not limited to list above.<\/p>\n
The Complainant contends that the disputed domain name incorporates NOVARTIS well-known trademark in its entirety and therefore it is identical to the Complainant’s trademark.<\/p>\n
The Complainant contends that has never granted the Respondent any right to use the NOVARTIS trademark in the disputed domain name, nor is the Respondent affiliated to the Complainant in any form.<\/p>\n
The Complainant adds that there is no evidence that the Respondent is known by the disputed domain name or owns any corresponding registered trademarks. The Registrant name “Frank Disk” does not correspond to the disputed domain name nor the name “Novartis”. When conducting online trademark databases searches, no information is found in relation to trademarks corresponding to the terms “novartis.cfd” or “novartis cfd”.<\/p>\n
The Complainant asserts that when searching on popular Internet search engines for the terms “novartis”, alone or in combination with the term “cfd”, the vast majority of the results directly relate to the Novartis group, the Complainant as well as its website, its social medias accounts or related topics.<\/p>\n
The Complainant contends that the disputed domain name resolves to a Pay-Per-Click page (“PPC page”). PPC pages generate revenues when Internet users click on the links displayed on the page. The PPC page associated to the disputed domain displays relevant sponsored links which clearly refer to the Complainant and its business activity as they are entitled “Pharma”, “Pharma Agenturen”, “Pharma Ausbildung” and “Sandoz”. The Respondent is very likely obtaining a financial benefit when Internet users are clicking on the aforementioned links. Such use of the disputed domain name aims at attracting Internet users for commercial gain by creating a likelihood of confusion with the Complainant’s NOVARTIS trademark as to the sources, sponsorship, affiliation, or endorsement of the aforementioned PPC page. When “the business model in this case, was for the Respondent to passively collect click-through revenue generated solely from the Complainant’s goodwill and Internet users’ inaccurate guessing of the correct domain name associated with the Complainant’s RENAULT financial services”, it has been held that the “[e]xploitation of the reputation of a trademark to obtain click-through commissions from the diversion of Internet users is a common example of use in bad faith as referred to in paragraph 4(b)(iv) of the Policy and identified in many previous UDRP decisions” (see Renault SAS v. Domain Administrator, See PrivacyGuardian.org \/ Simon Pan, WIPO Case No. D2019-3208). Moreover, when the use of the disputed domain name was in connection with “a parking page displaying PPC links, from which Respondent derived click-through revenue”, the UDRP Panel considered that such use “signals a further attempt on the part of Respondent to take unauthorized commercial advantage of Complainant’s trademarks in bad faith” (see Amazon Technologies, Inc. and Amazon Europe Core S.à.r.l. v. Hei Ze Shang Zi, WIPO Case No. D2020-3012).<\/p>\n
The Complainant assumes that it the Respondent deliberately chose to use NOVARTIS well-known trademark in the disputed domain name to benefit from the Complainant’s worldwide renown trademark and to confuse Internet users as to the source of the disputed domain name and the associated web page. Such use of the disputed domain name cannot therefore be considered as a bona fide<\/em> offering of goods or services nor as legitimate noncommercial or fair.<\/p>\n The Complainant contends that ïts trademark registrations predate the registration of the disputed domain name, and the Respondent has never been authorized by the Complainant to register the disputed domain name. The Respondent registered the disputed domain name many years after the registrations of the Complainant’s NOVARTIS trademark. The NOVARTIS trademark is a widely known trademark registered in many countries and the Complainant enjoys a strong online presence. The Novartis group especially owns and used the domain name <novartis.us> which redirects Internet users to a dedicated web page (https:\/\/www.novartis.co m\/us-en\/), which is part of its main website at <novartis.com>, especially intended for an audience in the United States and informing on the Novartis group presence and activities in this country. The Complainant is very active on social media to promote its mark, products and services (See, Laboratoires M&L v. Zhaoxingming, CAC Case No. 102277). By conducting a simple online search regarding the name “Novartis” alone or in combination with the term “cfd” on popular search engines, the Respondent would have inevitably learnt about the Complainant, its trademark and business (see Intesa Sanpaolo S.p.A. v. Abayomi Ajileye, CAC Case No. 102396).<\/p>\n Moreover, as indicated above, the Novartis group has an established business presence in United States, via its subsidiaries and associated companies, country where the Respondent is based.<\/p>\n Therefore, according to the Complainant, the Respondent had knowledge of the Complainant and the NOVARTIS trademark at the time of the registration of the disputed domain name. It appears that the Respondent registered the disputed domain name in bad faith.<\/p>\n <\/p>\n The Complainant states that the disputed domain name resolves to a PPC page which is likely to generate revenues when Internet users click on the links displayed therein. The Respondent is obtaining a financial benefit when Internet users are clicking on the aforementioned links. Such use of the disputed domain name aims at attracting Internet users for commercial gain by creating a likelihood of confusion with the Complainant’s NOVARTIS trademark as to the sources, sponsorship, affiliation, or endorsement of the aforementioned PPC page. In that regard, the Complainant contends that the Respondent is using the disputed domain name in bad faith.<\/p>\n The Complainant asserts that the Respondent is likely trying to conceal Its identity regarding the ownership of the disputed domain name – as his name and contact details are covered by a privacy shield in the corresponding Whois record – which is further evidence of bad faith (Instagram, LLC v. Registration Private, Domains By Proxy, LLC \/ Murat Sander, WIPO Case No. D2021-0526).<\/p>\n Furthermore, on September 12, 2022, the Complainant sent a cease-and-desist letter to the Respondent informing of the Complainant’s rights regarding the NOVARTIS trademark. On September 13, 2022, the Respondent replied asking “how should [the Parties] go about it”. On October 21, 2022, the Complainant offered to the Respondent to settle the matter amicably. In this regard, the Complainant invited the Respondent to provide the authorization code related to the disputed domain name to enable the corresponding transfer from the Respondent to the Complainant. On November 10, 2022, the Respondent sent the authorization code to the Complainant. However, as the disputed domain name was locked, on the same day the Complainant wrote to the Respondent that it takes actions before the Registrar to unlock the disputed domain name. The Complainant sent three reminders via emails to the Respondent to which the latter did not reply.<\/p>\n The aforementioned facts demonstrate that the Respondent has been using the disputed domain name in bad faith.<\/p>\n The overall described circumstances are clear demonstration of the registration and use of the disputed domain name are in bad faith.<\/p>\n <\/p>\n RESPONDENT:<\/p>\n No administratively Complaint Response has been filed.<\/p>",
"rights": " The Complainant has, to the satisfaction of the Panel, shown the disputed domain name is identical or confusingly similar to a trademark or service mark in which the Complainant has rights (within the meaning of paragraph 4(a)(i) of the UDRP).<\/p>",
"no_rights_or_legitimate_interests": " The Complainant has, to the satisfaction of the Panel, shown the Respondent to have no rights or legitimate interests in respect of the disputed domain name (within the meaning of paragraph 4(a)(ii) of the UDRP).<\/p>",
"bad_faith": " The Complainant has, to the satisfaction of the Panel, shown the disputed domain name has been registered and is being used in bad faith (within the meaning of paragraph 4(a)(iii) of the UDRP).<\/p>",
"procedural_factors": " The Panel is satisfied that all procedural requirements under UDRP were met and there is no other reason why it would be inappropriate to provide a decision.<\/p>",
"decision": "Accepted",
"panelists": [
"Radim Charvát"
],
"date_of_panel_decision": "2023-04-18 00:00:00",
"informal_english_translation": " The Complainant is the owner of the following trademark registrations:<\/p>\n The Complainant proved its ownership of listed trademark registrations by the submitted extracts from the Registers.<\/p>",
"decision_domains": {
"novartis.cfd": "TRANSFERRED"
},
"panelist": null,
"panellists_text": null
}\n
<\/u><\/li>\n\n
\n